Latest Cell Therapy News

Page 1 of 17
Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
Victor Sage
Victor Sage
17 Nov 2026
AdAlta has taken ownership of the US FDA Orphan Drug Designation for EW-001, strengthening the commercial case for its mesothelioma CAR-T therapy. The designation follows a constructive pre-IND meeting, but approval and clinical success remain unproven.
Ada Torres
Ada Torres
17 Nov 2026
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026
Miro Sciences says Australia’s medicines regulator has completed its inspection of the manufacturing site for StemSmart, supporting the company’s planned Phase 2 Crohn’s disease trial. The inspection is a significant readiness step, but it is not itself approval to begin the study or confirmation of a successful audit outcome.
Ada Torres
Ada Torres
12 Nov 2026
AdAlta has received a larger-than-expected A$1.396 million R&D Tax Incentive refund tied to overseas work on its EW-001 CAR-T therapy. The non-dilutive cash arrives before Australian manufacturing and expected FDA pre-IND meeting minutes in December.
Ada Torres
Ada Torres
12 Nov 2026
Cynata Therapeutics will raise approximately $912,962 after shareholders subscribed for just 25.8% of its fully underwritten entitlement offer. Caravel Securities will fund the remaining shortfall, leaving the biotech reliant on the underwriter to complete the raise.
Ada Torres
Ada Torres
30 Oct 2026
Chimeric Therapeutics has stopped enrolment and dosing in its CHM-2101 CAR-T trial after a safety review found the highest dose unsafe. With $1.35 million in cash, suspended securities and uncertain creditor negotiations, the company is now pursuing a possible recapitalisation while preserving a preclinical CDH17 pathway.
Ada Torres
Ada Torres
29 Oct 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
Ada Torres
Ada Torres
27 Oct 2026
NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.
Ada Torres
Ada Torres
27 Oct 2026
Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.
Ada Torres
Ada Torres
27 Oct 2026
AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.
Ada Torres
Ada Torres
26 Oct 2026

Browse the archive

Full archive